Why INDP Stock dropped -7.48% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, INDP holds an RQD Score of 44 out of 100, a letter grade of D, and the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars: the Fundamental Cash Engine scores 7 / 20 (ROIC -35%; FCF yield -2.89%), the Whale 13F Flow scores 13 / 20 (institutional accumulation and options positioning), Insider Conviction scores 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 11 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and insider conviction, which together signal that the company is consuming cash without current operating returns and that insiders are not showing conviction in the stock. The institutional flow pillar is the strongest relative to its ceiling, but it does not offset the negative fundamental picture. The Altman Z of 2.5 and Piotroski F of 2/9 point to a balance sheet that warrants close scrutiny. The rating is a framework summary of the source data and is not a personalized recommendation.

Per the SEC financials, operating losses widened from $-16.4M in FY 2023 to $-19.8M in FY 2025, and free cash flow was negative in each reported period. Per the market data, margins are reported as 0% for gross, operating, and net, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating. Cash increased from $5.8M to $8.5M between FY 2024 and FY 2025. Debt/Equity is 0.5 per the forensic pillar, while reported debt values in the financials are N/A.

Per the news wire, the most recent item is a $24 million private placement of common stock, reported as completed. Other headlines report that the stock slid 7.49% to $3.09 as shares tested lower support, and a Q4 2025 earnings report described a wider-than-expected loss that was met with a sharp 29% stock rally. Two items are tagged as catalysts (green) and the remaining items as market wire (yellow). The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals. Risk watch items include the widening operating loss, negative free cash flow, and the sensitivity of the stock to financing events.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be assessed from the source data. Sector correlation is limited to the beta of 1.0 and the Health Care classification. A second-order item to monitor is the dilutive effect of equity financing on per-share metrics, given the completed $24 million private placement and the absence of reported EPS.

• What are the company's products, development stage, and any regulatory milestones? The source data contains no business description beyond sector and industry.
• What is the size and terms of the $24 million private placement, and how many shares were issued?
• Why are EPS, debt, and forward P/E reported as N/A or not available, and what are the outstanding share count and cash runway?
• What is driving the cash increase in FY 2025 given negative free cash flow, and what is the current cash runway?
• Who are the institutional holders and insiders, and what are their recent transactions?